Advancing Pharmacovigilance Practice in Africa: Moving from Data Collection to Data-Driven Decision Making-Report from the 5th ISoP Africa Chapter Meeting
- PMID: 40783895
- DOI: 10.1007/s40264-025-01598-7
Advancing Pharmacovigilance Practice in Africa: Moving from Data Collection to Data-Driven Decision Making-Report from the 5th ISoP Africa Chapter Meeting
Conflict of interest statement
Declarations. Funding: No funding was provided for writing this article. Conflict of interest: The authors declare no conflicts of interest related to the content of this meeting report and regarding the publication of this paper. Ethical approval: Not applicable. Consent to participate: Not applicable. Consent for publication: The authors all give consent for publication. Availability of data and material:: Data sharing does not apply to this article as no datasets were generated or analyzed as part of the meeting. Code availability: Not applicable. Author contributions: HBN, SA, JM, JA, EK and DN wrote the initial draft of the report. HBN, GTS, CO, JMP, NK, MR, VPN, CA, DA, PUB, WM, JCM, CK, JA and EK conceptualized and planned the meeting as the Scientific committee. HBN, GTS, CO, JMP, NK, MR, VPN, CA, DA, PUB, WM, JCM, CK, OA and ACR reviewed and revised the draft. All authors approved the final version of the report. Meeting website: Link to the meeting website https://isopafrica.com/
References
-
- (ISOP) ISoP. International Society of Pharmacovigilance. 2025. https://isoponline.org/# .
-
- Nambasa VP, Gunter HM, Adeyemo MB, Bhawaneedin NY, Blockman M, Sabblah GT, et al. Empowering African expertise: enhancing safety data integration and signal detection for COVID-19 vaccines through the African union smart safety surveillance Joint Signal Management Group. Drug Saf. 2025;48(3):233–49. - PubMed - PMC
-
- Russom M, Bahta I, Debesai M. Eritrean pharmacovigilance system: key strategies, success stories, challenges and lessons learned. Drug Saf. 2021;44(10):1021–32. - PubMed
-
- Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, et al. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015;15(7):793–802. - PubMed